### PharmaPendium®
#### 2018.23 Release

The content release includes the following updates

<table>
<thead>
<tr>
<th>Legend</th>
<th>Content Updates</th>
<th>Data Updates</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### The new totals for PharmaPendium are:
- 2,536,236 pages of FDA Approval documents (Including FDA Classic Collection)
- 115,975 documents of FDA Approval documents (Including FDA Classic Collection)
- 4,565 drugs with data in PharmaPendium
- 1,832,998 extracted safety data lines
- 1,712,465 extracted PK data lines
- 338,690 extracted ME data lines
- 2,919,617 extracted Efficacy data lines
- 1,832,998 extracted Activity data lines
- 12,285,594 FAERS (post-marketing) reports
- 12,879 documents / 235,642 pages of EMA Approval documents
- 18,176 documents / 715,027 pages of FDA Advisory Committees Meetings documents
- 10,906 documents / 308,149 pages of FDA Classic Collection
- 2,769 documents / 32,290 pages of DESI documents

### 1. FDA Approval Documents
- 208 new FDA Approval Documents
- 3,113 new pages of FDA Approval Documents

### 2. Extracted PK Data Observations
- 8,572 new extracted PK data lines

### 3. Extracted Safety Data Observations
- 4,132 new extracted safety data lines

### 4. Metabolizing Enzymes Database
- 1,254 new ME extracted data lines

### 5. Published Toxicity Database
- 170 new safety records

### 6. FAERS
- 405,214 new FAERS reports (2018_Q3)

### 7. Copyright © 2018 Elsevier Life Sciences IP Limited. All rights reserved. PharmaPendium is a trade mark of Elsevier Life Sciences IP Limited. RELX Group and the RE symbol are trade marks of RELX Group plc, used under license. December 2018